Irritable bowel syndrome phenotypes: leading factors of genetics and epigenetics, mechanisms of formation
- 作者: Gaus O.1, Livzan M.1
-
隶属关系:
- Omsk State Medical University
- 期: 卷 95, 编号 2 (2023)
- 页面: 164-172
- 栏目: Original articles
- URL: https://journals.rcsi.science/0040-3660/article/view/132901
- DOI: https://doi.org/10.26442/00403660.2023.02.202111
- ID: 132901
如何引用文章
全文:
详细
Aim. To develop individualized approaches to the treatment of irritable bowel syndrome (IBS) based on the interaction of genetic and epigenetic factors, to characterize the phenotypes of the disease.
Materials and methods. According to the formulated concept of the authors, from the cohort of patients with IBS, subgroups were distinguished – “post-infectious IBS” (n=45), “IBS in overweight and obese people” (n=49), “comorbid IBS” (n=75) and “essential IBS” (n=51). In each subgroup the prevalence of candidate gene polymorphisms associated with IBS (COMT, SLC6A4, FTO), nutritional habits, levels of anxiety and depression, secretion of cortisol, serotonin, dopamine and zonulin levels in feces were studied.
Results. Patients with “post-infectious IBS” are characterized by the carriage of the S allele of the SLC6A4 gene, the val/val genotype of the COMT gene, the prevalence of diarrhea, a high level of anxiety and frequent refusal of milk and dairy products. The phenotype “IBS in overweight and obese individuals” is characterized by L/L genotypes of the SLC6A4 gene, met/met of the COMT gene and A/A of the FTO gene, constipation, low plasma dopamine levels, signs of depression, frequent episodes of overeating, addiction to fatty and sweet foods, excessive consumption of sugar, lack of vegetables in the diet. The “comorbid IBS phenotype” is characterized by more frequent detection of the val/val genotype of the COMT gene and the carriage of the S allele of the SLC6A4 gene, clinically pronounced anxiety and depression, early onset of the disease, severe course, significant food restrictions and significant increase in epithelial permeability. With the “essential phenotype”, there are no bright stigmas of the disease; it is not possible to identify distinctive genetic and epigenetic factors, as well as the leading pathogenetic mechanism.
Conclusion. The analysis of genetic and epigenetic factors, the leading mechanisms of the formation and course of IBS allows us to identify additional (except for “postinfectious”) phenotypes of the disease: “IBS in overweight and obese people”, “comorbid” and “essential”.
作者简介
Olga Gaus
Omsk State Medical University
编辑信件的主要联系方式.
Email: gaus_olga@bk.ru
ORCID iD: 0000-0001-9370-4768
SPIN 代码: 7116-8419
Scopus 作者 ID: 56598554900
Researcher ID: AAB-1979-2019
Cand. Sci. (Med.), Docent, Associate Professor of the Department of Faculty Therapy and Gastroenterology
俄罗斯联邦, OmskMaria Livzan
Omsk State Medical University
Email: mlivzan@yandex.ru
ORCID iD: 0000-0002-6581-7017
SPIN 代码: 1961-4082
Scopus 作者 ID: 24341682600
MD, Dr. Sci. (Med.), Professor, Corresponding Member Russian Academy of Sciences
俄罗斯联邦, Omsk参考
- Black CJ, Ford AC. Global burden of irritable bowel syndrome: trends, predictions and risk factors. Nat Rev Gastroenterol Hepatol. 2020;17(8):473-86. doi: 10.1038/s41575-020-0286-8
- Frändemark Å, Törnblom H, Jakobsson S, Simrén M. Work Productivity and Activity Impairment in Irritable Bowel Syndrome (IBS): A Multifaceted Problem. Am J Gastroenterol. 2018;113(10):1540-9. doi: 10.1038/s41395-018-0262-x
- Ballou S, McMahon C, Lee HN, et al. Effects of Irritable Bowel Syndrome on Daily Activities Vary Among Subtypes Based on Results From the IBS in America Survey. Clin Gastroenterol Hepatol. 2019;17(12):2471-8.e3. doi: 10.1016/j.cgh.2019.08.016
- Weerts ZZRM, Vork L, Mujagic Z, et al. Reduction in IBS symptom severity is not paralleled by improvement in quality of life in patients with irritable bowel syndrome. Neurogastroenterol Motil. 2019;31(8):e13629. doi: 10.1111/nmo.13629
- Spiegel BM, Gralnek IM, Bolus R, et al. Clinical determinants of health-related quality of life in patients with irritable bowel syndrome. Arch Intern Med. 2004;164(16):1773-80. doi: 10.1001/archinte.164.16.1773
- Mahurkar-Joshi S, Chang L. Epigenetic Mechanisms in Irritable Bowel Syndrome. Front Psychiatry. 2020;11:805. doi: 10.3389/fpsyt.2020.00805
- Videlock EJ, Chang L. Latest Insights on the Pathogenesis of Irritable Bowel Syndrome. Gastroenterol Clin North Am. 2021;50(3):505-22. doi: 10.1016/j.gtc.2021.04.002
- Barbara G, Grover M, Bercik P, et al. Rome Foundation Working Team Report on Post-Infection Irritable Bowel Syndrome. Gastroenterology. 2019;156(1):46-58.e7. doi: 10.1053/j.gastro.2018.07.011
- Zhang Y, Li L, Guo C, et al. Effects of probiotic type, dose and treatment duration on irritable bowel syndrome diagnosed by Rome III criteria: a meta-analysis. BMC Gastroenterol. 2016;16(1):62. doi: 10.1186/s12876-016-0470-z
- Pinto-Sánchez MI, Smecuol EC, Temprano MP, et al. Bifidobacterium infantis NLS Super Strain Reduces the Expression of α-Defensin-5, a Marker of Innate Immunity, in the Mucosa of Active Celiac Disease Patients. J Clin Gastroenterol. 2017;51(9):814-7. doi: 10.1097/MCG.0000000000000687
- Гаус О.В., Ливзан М.А. «Гастроинтестинальная» коморбидность при синдроме раздраженного кишечника. Экспериментальная и клиническая гастроэнтерология. 2021;190(6):104-11 [Gaus OV, Livzan MA. “Gastrointestinal” comorbidity in irritable bowel syndrome. Eksperimental'naia i klinicheskaia gastroenterologiia. 2021;190(6):104-11 (in Russian)]. doi: 10.31146/1682-8658-ecg-190-6-104-111
- Гаус О.В., Ливзан М.А. Влияние социодемографических факторов, пищевых привычек и психологического статуса на развитие синдрома раздраженного кишечника. Профилактическая медицина. 2022;25(11):84-91 [Gaus OV, Livzan MA. Social and demographic factors, eating habits, and psychological status in developing irritable bowel syndrome. Profilakticheskaia medicina. 2022;25(11):84-91 (in Russian)]. doi: 10.17116/profmed20222511184
- Федорин М.М., Ливзан М.А., Гаус О.В. Синдром раздраженного кишечника у лиц с избыточной массой тела и ожирением: новый фенотип заболевания? Доказательная гастроэнтерология. 2021;10(2):52-60 [Fedorin MM, Livzan MA, Gaus OV. IBS in overweight and obese individuals: a new disease phenotype? Dokazatel’naia gastroenterologiia. 2021;10(2):52-60 (in Russian)]. doi: 10.17116/dokgastro20211002152
- Федорин М.М., Ливзан М.А., Гаус О.В. Клинические особенности и пищевые предпочтения у лиц с синдромом раздраженного кишечника на фоне избыточной массы тела и ожирения. Consilium Medicum. 2022;24(5):306-11 [Fedorin ММ, Livzan MA, Gaus OV. Clinical features and food preferences in persons with irritable bowel syndrome against the background of overweight and obesity. Consilium Medicum. 2022;24(5):306-11 (in Russian)]. doi: 10.26442/20751753.2022.5.201730
- Ивашкин В.Т., Маев И.В., Шелыгин Ю.А., и др. Диагностика и лечение синдрома раздраженного кишечника (Клинические рекомендации Российской гастроэнтерологической ассоциации и Ассоциации колопроктологов России). Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2021;31(5):74-95 [Ivashkin VT, Maev IV, Shelygin YuA, et al. Diagnosis and Treatment of Irritable Bowel Syndrome: Clinical Recommendations of the Russian Gastroenterological Association and Association of Coloproctologists of Russia. Rossiiskii zhurnal gastroienterologii, gepatologii, koloproktologii. 2021;31(5):74-95 (in Russian)]. doi: 10.22416/1382-4376-2021-31-5-74-95
- Camilleri M. Leaky gut: mechanisms, measurement and clinical implications in humans. Gut. 2019;68(8):1516-26. doi: 10.1136/gutjnl-2019-318427
- Odenwald MA, Turner JR. The intestinal epithelial barrier: a therapeutic target? Nat Rev Gastroenterol Hepatol. 2017;14(1):9-21. doi: 10.1038/nrgastro.2016.169
- Spiller R, Garsed K. Postinfectious irritable bowel syndrome. Gastroenterology. 2009;136(6):1979-88. doi: 10.1053/j.gastro.2009.02.074
- Rusu F, Mocanu L, Dumitraşcu DL. Phenotypic features of patients with post-infectious irritable bowel syndrome. Med Pharm Rep. 2019;92(3):239-45. doi: 10.15386/mpr-1317
- Nielsen HL, Engberg J, Ejlertsen T, Nielsen H. Psychometric scores and persistence of irritable bowel after Campylobacter concisus infection. Scand J Gastroenterol. 2014;49(5):545-51. doi: 10.3109/00365521.2014.886718
- Ghoshal UC, Shukla R, Ghoshal U. Small Intestinal Bacterial Overgrowth and Irritable Bowel Syndrome: A Bridge between Functional Organic Dichotomy. Gut Liver. 2017;11(2):196-208. doi: 10.5009/gnl16126
- Kumar S, Ranjan P, Mittal B, Ghoshal UC. Serotonin transporter gene (SLC6A4) polymorphism in patients with irritable bowel syndrome and healthy controls. J Gastrointestin Liver Dis. 2012;21(1):31-8.
- Spiller R, Lam C. An Update on Post-infectious Irritable Bowel Syndrome: Role of Genetics, Immune Activation, Serotonin and Altered Microbiome. J Neurogastroenterol Motil. 2012;18(3):258-68. doi: 10.5056/jnm.2012.18.3.258
- Kibune Nagasako C, Garcia Montes C, Silva Lorena SL, Mesquita MA. Irritable bowel syndrome subtypes: Clinical and psychological features, body mass index and comorbidities. Rev Esp Enferm Dig. 2016;108(2):59-64. doi: 10.17235/reed.2015.3979/2015
- Lee CG, Lee JK, Kang YS, et al. Visceral abdominal obesity is associated with an increased risk of irritable bowel syndrome. Am J Gastroenterol. 2015;110(2):310-9. doi: 10.1038/ajg.2014.422
- Fysekidis M, Bouchoucha M, Bihan H, et al. Prevalence and co-occurrence of upper and lower functional gastrointestinal symptoms in patients eligible for bariatric surgery. Obes Surg. 2012;22(3):403-10. doi: 10.1007/s11695-011-0396-z
- Liu DR, Xu XJ, Yao SK. Increased intestinal mucosal leptin levels in patients with diarrhea-predominant irritable bowel syndrome. World J Gastroenterol. 2018;24(1):46-57. doi: 10.3748/wjg.v24.i1.46
- Russo F, Chimienti G, Clemente C, et al. Adipokine profile in celiac patients: differences in comparison with patients suffering from diarrhea-predominant IBS and healthy subjects. Scand J Gastroenterol. 2013;48(12):1377-85. doi: 10.3109/00365521.2013.845907
- Pickett-Blakely O. Obesity and irritable bowel syndrome: a comprehensive review. Gastroenterol Hepatol (N Y). 2014;10(7):411-6.
- Talley NJ, Quan C, Jones MP, Horowitz M. Association of upper and lower gastrointestinal tract symptoms with body mass index in an Australian cohort. Neurogastroenterol Motil. 2004;16(4):413-9. doi: 10.1111/j.1365-2982.2004.00530.x
- Barberio B, Yiannakou Y, Houghton LA, et al. Overlap of Rome IV Irritable Bowel Syndrome and Functional Dyspepsia and Effect on Natural History: A Longitudinal Follow-Up Study. Clin Gastroenterol Hepatol. 2022;20(2):e89-101. doi: 10.1016/j.cgh.2021.04.011
- Lee JY, Kim N, Park JH, et al. Sex and Gender Differences in Overlap Syndrome of Functional Gastrointestinal Disorder and Effect of Genetic Polymorphisms in South Korea: A Long-term Follow-up Study. J Neurogastroenterol Motil. 2022;28(1):145-58. doi: 10.5056/jnm21047